A PSA-guided approach for a better diagnosis of prostatic adenocarcinoma based on MALDI profiling and peptide identification

Chiara Fania, Ilaria Sogno, Michele Vasso, Enrica Torretta, Roberta Leone, Antonino Bruno, Paolo Consonni, Adriana Albini, Cecilia Gelfi

Research output: Contribution to journalArticle

Abstract

Background: Prostate cancer (PCa) is the second cause of mortality in men worldwide. The prostate-specific antigen (PSA) test is routinely adopted in diagnosis; nevertheless more reliable biomarkers are continuously under investigation by monitoring the release of molecules into the bloodstream. The serum protein profiles appear to provide cancer-specific fingerprints that help to discriminate patients (especially with low PSA level) from controls, improving the performance of existing clinical tests. Methods: Samples from healthy controls and PCa patients with low (≤. 4. ng/mL) and high PSA (>. 4. ng/mL) levels were analyzed by MALDI profiling, and by a multi fractionation approach coupled to ESI-MS for peaks identification. Results: MALDI profiling achieved to detect 10 and 14 changed peaks (p-value

Original languageEnglish
Pages (from-to)42-49
Number of pages8
JournalClinica Chimica Acta
Volume439
DOIs
Publication statusPublished - Oct 12 2014

Keywords

  • Complement C3f
  • Immunodepletion
  • MALDI profiling
  • Prostate cancer
  • Prostate-specific antigen

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical
  • Medicine(all)

Fingerprint Dive into the research topics of 'A PSA-guided approach for a better diagnosis of prostatic adenocarcinoma based on MALDI profiling and peptide identification'. Together they form a unique fingerprint.

  • Cite this